Ubs Asset Management Americas Inc Arcus Biosciences, Inc. Transaction History
Ubs Asset Management Americas Inc
- $446 Billion
- Q3 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 87,771 shares of RCUS stock, worth $1.76 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
87,771
Previous 173,598
49.44%
Holding current value
$1.76 Million
Previous $1.41 Million
15.57%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding RCUS
# of Institutions
212Shares Held
67.7MCall Options Held
3.3MPut Options Held
146K-
Black Rock Inc. New York, NY9.76MShares$196 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.63MShares$133 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.33MShares$87 Million0.12% of portfolio
-
Woodline Partners LP San Francisco, CA3.77MShares$75.7 Million0.26% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$74 Million1.51% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.45B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...